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ABSTRACT
Objective: Autopsy cases show that cortical lesions (CLs) in multiple sclerosis (MS) lack lympho-
cyte/macrophage influx, blood-brain barrier breakdown, and complement activation. However,
some CLs were demonstrated to harbor activated microglia. Here, we assessed the clinical signif-
icance of microglia activation in CLs in a large autopsy sample, and we investigated possible
interrelationships with other pathologic characteristics.
Methods: We cross-sectionally investigated the clinicopathologic characteristics of 22 patients
with MS with extensive subpial demyelination (CL group) and 19 patients with MS with only little
demyelination of the cerebral cortex (non-CL group).
Results: A subset of the patients in the CL group (12 patients) showed rims of activated microglia
(RAM) at the border of the CLs (RAM-CL group), whereas the other 10 patients in this group did
not show microglia activation (nonRAM-CL group). A subsequent comparison between groups
showed that patients with MS harboring RAM-CLs were significantly younger at the time of their
death (53.5 years) than patients harboring mainly non–RAM-CLs (68.7 years; p  0.05) or pa-
tients without extensive numbers of CLs (66.9 years; p0.01). In addition, a significantly shorter
disease duration was found for the RAM-CL group (mean 20.9 years) than for the non-CL group
(mean 34.5 years; p  0.05). We also found that the presence of RAM-CLs is associated with a
higher number of chronic active white matter (WM) lesions (Spearman  0.74; p 0.0001).
Conclusions: RAM-CLs were found in a subset of patients with MS who also have more active WM
inflammation and a less favorable disease course. Neurology® 2012;79:1369–1376
GLOSSARY
ANOVA  analysis of variance; BSA  bovine serum albumin; CL  cortical lesion; HLA  human leukocyte antigen; MS 
multiple sclerosis; PBS phosphate-buffered saline; PLP proteolipid protein; PP primary progressive; PR progressive
relapsing; RAM rim of activated microglia; SP secondary progressive; WMLwhite matter lesion.
Gray matter pathology in multiple sclerosis (MS) contributes importantly to clinical disability
and cognitive decline1–6 and increases substantially with progression of disease.7,8
Subpial cortical lesions (CLs) are by far the most common CL type in MS brains.9,10 What
causes subpial CLs to develop is poorly understood so far, but because of their superficial
localization, it has been suggested that myelinotoxic substances that are produced as a result of
inflammation in the meninges might be a contributing factor.10–12 Although significant inflam-
mation can indeed be found in the MS meninges,13 we were previously unable to show an
association between meningeal inflammation and the presence or extent of subpial cortical
demyelination in chronic MS.13
CLs are generally devoid of inflammation,11,14,15 and the blood-brain barrier is intact.16
However, it should be noted that these facts are especially true for autopsy material, because a
recent biopsy study using material from patients with early MS with tumefactive lesions17
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demonstrated that early cortical demyelina-
tion, such as white matter demyelination,
may be characterized by profound T-cell in-
filtration, as well as the presence of foamy
macrophages.17
Despite the reported lack of inflammation
in CLs in postmortem MS tissue,11,14–16 sev-
eral pathologic studies reported activated mi-
croglia at the borders of CLs.11,14 The clinical
and pathologic significance of these activated
microglia in CLs is, however, so far unclear.
In this large autopsy study, clinical and patho-
logic profiles of patients with MS with vary-
ing extents of cortical demyelination and
different types of CLs, including those with a
rim of activated microglia (RAM-CLs), were
investigated.
METHODS Postmortem tissue and lesion classification.
Brain material was obtained from The Netherlands Brain Bank,
Amsterdam, the Netherlands. A total of 1,036 paraffin-
embedded tissue blocks from 41 patients with MS were investi-
gated in the study. Blinded to the patients’ clinical statuses, 22
patients with MS were selected for the presence of extensive sub-
pial cortical demyelination (CL group),18 and 19 patients with
MS were selected based on a lack of extensive subpial cortical
demyelination (non-CL group). The number of white matter
lesions (WMLs) in the 22 patients in the CL group was deter-
mined in a total of 639 tissue blocks. In a subset of these tissue
blocks, selected based on the presence of cerebral cortex (random
selection), the percentage of subpial cortical demyelination was
determined. A total of 102 tissue blocks, of which 19 tissue
blocks were full hemispheric tissue blocks and 83 were standard-
sized tissue blocks, were examined for the extent of subpial corti-
cal demyelination. The number of WMLs of the 19 patients
with MS in the non-CL group was determined in a total of 397
tissue blocks. From a subset of the 397 tissue blocks examined
for the non-CL group, namely 90 tissue blocks, the percentages
of subpial cortical demyelination were determined. From these
90 tissue blocks, 19 tissue blocks were full hemispheric tissue
blocks and 71 were standard-sized tissue blocks. Clinical data for
both groups are summarized in table 1.
The age of patients with MS at the time of death ranged
from 41 to 88 years (mean  SD 63  13 years) with a mean
postmortem delay of 8 hours and 38 minutes (SD 3 hours and
29 minutes).
Based on immunohistochemical stainings for major histo-
compatibility complex II (microglia and macrophages) and
proteolipid protein (PLP) (myelin/demyelination) (see Immuno-
histochemistry), a distinction was made between active, chronic
active, or inactive WMLs and RAM-CLs or non–RAM-CLs (fig-
ures 1 and 2, respectively).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the local institutional
ethics review board. Before death, all donors or their next of kin
provided written informed consent for brain autopsy and use of
material and clinical information for research purposes.
Table 1 Clinical data of patients with MS included in this study
Group and
patient
Age,
y
Type
of MS Sex
Disease
duration, y Cause of death
NonRAM-CL
1 69 PP M 34 Cardiac arrest
2 57 ND F 25 Euthanasia
3 75 SP F 33 Pneumonia
4 77 PP M 27 CVA
5 71 ND F 25 Postsurgery respiratory problems
6 55 PP F 19 Possible CVA
7 84 ND F 49 Euthanasia
8 70 ND M 51 Cardiac arrest
9 70 PP F 40 Urinary tract infection
10 59 SP F 25 Euthanasia
RAM-CL
1 56 SP M 27 Pneumonia
2 66 ND M Unknown Sepsis
3 47 SP M 7 Urosepsis
4 66 SP F 23 Unknown
5 49 SP M 26 Pneumonia by MS
6 61 SP M 17 Euthanasia
7 44 PP M 16 Pneumonia
8 44 SP M 21 General deterioration due to MS
9 57 SP F 27 Respiratory insufficiency
10 43 PP M 17 Pneumonia
11 68 PP F 38 Aspiration pneumonia
12 41 SP F 11 General deterioration due to MS
Non-CL
1 65 PR M 25 Urosepsis
2 66 PP F 43 Metastasis
3 81 PP M 59 General deterioration
4 48 PP F 48 Euthanasia
5 49 PP F 30 Metastasized breast carcinoma
6 73 PP M 16 Shock
7 59 SP M 32 Myocardial infarct
8 49 PP F 27 Metastasis of cervical carcinoma
9 68 PP F 43 CVA
10 77 PP F 48 Pneumonia
11 44 PP F 8 Decompensation
12 77 ND F ND Respiratory insufficiency with
aspiration pneumonia
13 63 PP M 27 Cardiac arrest
14 76 PP F 19 Unknown
15 66 PP M 26 Unknown
16 57 PP M 25 Euthanasia
17 88 PP F 25 Exhaustion by chronic colitis
18 81 PP F 45 Sepsis by aspiration pneumonia
19 84 PP F 49 Unknown
Abbreviations: CL cortical lesion; CVA cerebrovascular accident; MSmultiple sclero-
sis; NDMS subtype not determined; PP primary progressive; PR progressive relaps-
ing; RAM rim of activated microglia; SP secondary progressive.
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Immunohistochemistry. Five-micrometer-thick paraffin sec-
tions were deparaffinized in a series of xylene (four 5-minute
rinses), 100% ethanol, 96% ethanol, and 70% ethanol. Endoge-
nous peroxidase activity was blocked by incubating the sections
in methanol with 0.3% H2O2 for 30 minutes. For primary im-
munostaining with anti-PLP (clone Plpc1; mouse immunoglob-
ulin G2a, 1:500; Serotec, Oxford, UK) sections were rinsed 3
times for 10 minutes each with phosphate-buffered saline (PBS)
followed by incubation with primary antibodies diluted in PBS
containing 1% bovine serum albumin (BSA) for 1 hour. For
primary immunostaining with antihuman leukocyte antigen
(HLA)-DR, sections were pretreated with microwave antigen re-
trieval (3 minutes at 900 W and 30 minutes at 180 W). After
pretreatment, sections were cooled to room temperature,
rinsed with PBS (three 10-minute rinses), and incubated with
antiHLA-DR (mouse immunoglobulin G2b, 1:50; gift from
Dr. Hilgers, VU Medical Center, Amsterdam, the Netherlands)
diluted in PBS containing 1% BSA for 1 hour. Then sections
were rinsed again with PBS (three 10-minute rinses) and incu-
bated with EnVision horseradish peroxidase complex (DAKO,
Glostrup, Denmark) and finally with 3,3 diaminobenzidine-
tetrahydrochloride dihydrate (DAKO) as a chromogen. After a
short rinse with tap water, sections were counterstained with
hematoxylin for 1 minute and intensely washed with tap water
for 5 minutes.
Morphometric analysis and quantification. Based on
anti-PLP and antiHLA-DR immunostainings, all tissue sec-
tions were investigated for the presence of active, chronic active,
or inactive WMLs (figure 1) and subsequently counted (table 2).
Of note, leukocortical lesions were regarded as WMLs expand-
ing into the cortical gray matter. Furthermore, a subset of the
tissue blocks, containing cortical gray matter (see Postmortem
tissue and lesion classification), was analyzed for the presence of
Figure 1 White matter lesions
Based on immunohistochemical stainingswith anti-proteolipid protein (A, C, and E) and anti-human leukocyte antigenDR (B,
D, and F), white matter lesions were subdivided into active (A and B), chronic active (C and D), or inactive (E and F) white
matter lesions.
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RAM-CLs or non–RAM-CLs. The tissue sections harboring
CLs were photographed with a digital camera and a prepared
digital image was printed. The cortical area demyelinated in the
plane of the section was analyzed using light microscopy, and the
same orientation was applied for the tissue on printed slides.
Based on the serial section stained for HLA-DR, a distinction
was made between RAM-CLs and non–RAM-CLs. The area of
subpial demyelination was morphometrically measured on the
digital images using ImageJ software (NIH, Bethesda, MD;
http://rsb.info.nih.gov/ij/index.html).
Statistical analyses. GraphPad Prism software (GraphPad
Software, Inc., San Diego, CA) was used for the statistical analy-
ses. For normal distribution of data, analysis of variance
(ANOVA) with Bonferroni correction for multiple comparisons
was used to compare differences among the RAM-CL group,
non–RAM-CL group, and non-CL group. When normality was
not found, the nonparametric Kruskal-Wallis test was used with
a Dunn correction for multiple comparisons. Possible correla-
tions were investigated with the nonparametric Spearman rank
correlation (when data were not normally distributed) or Pear-
son correlation test (when data were normally distributed). Re-
sults were considered significant when p  0.05.
RESULTS Clinical and pathologic descriptives of the
MS autopsy cases. Of the 41 patients with MS in-
cluded in this study, 23 patients with MS had experi-
enced a primary progressive (PP) disease course, 11
patients with MS had a secondary progressive (SP)
disease course, 1 patient with MS had a progressive
relapsing (PR) course, and for 6 patients with MS the
disease course was not specified or could not be retro-
spectively determined from the medical records.
Mean age at death was 63.4 years (SD 13.0 years),
and the mean disease duration was 29.6 years (SD
12.7 years). Of the 41 patients with MS included, 22
patients with MS harbored extensive subpial demy-
elination as described previously,18 and these patients
were designated as the CL group for further analyses.
Nineteen patients with MS showed only very limited
cortical demyelination, and these patients were re-
garded as the non-CL group. Overall, there was no
difference in age at death or disease duration between
these 2 groups.
On average, of the patients with MS in the CL
group, 23.0% (SD 11.6%) of the cerebral cortex was
demyelinated (vs 0.5% [SD 0.7%] in the non-CL
group). A total of 639 tissue blocks were investigated
within the CL group, and these blocks showed 208
inactive, 252 chronic active, and 59 active WMLs
(figure 1, table 2). In 12 patients of this group, mi-
croglia activation at the borders of the CLs was regu-
larly found (figure 2, A and B, table 2); this subgroup
was therefore regarded as the RAM-CL group (mean
percentage of cortical demyelination with RAM was
37.3%) (figure 2, A and B, table 2), whereas in the
Figure 2 Cortical lesions
Based on immunohistochemical stainings with anti-proteolipid protein (A and C) and anti-human leukocyte antigen DR (B
and D), cortical lesions were subdivided into cortical lesions with rims of activated microglia (RAM) (A and B) or non-RAM
cortical lesions (C and D).
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remaining 10 patients of the CL group no microglia
activation at the border of the CLs was found at all
(regarded as the non–RAM-CL group) (figure 2, C
and D, table 2). Interestingly, in the RAM-CL
group, a significantly larger proportion of the cere-
bral cortex was demyelinated (mean 27.9%) com-
pared with that in the non–RAM-CL group (mean
17.1%; p  0.03). Neither RAM-CLs nor non–
RAM-CLs showed any preference for a specific topo-
graphical distribution or localization within the
cerebral cortex. Hence, either subpial lesion type
(i.e., RAM-CLs and non–RAM-CLs) could be found
at the surface of the cortex and also within deep sulci
(data not shown). In the non-CL group, a total of
397 tissue blocks were investigated in which 123 in-
active, 64 chronic active, and 9 active WMLs were
subsequently found (figure 1, table 2).
Clinical profiles: comparisons between the RAM-CL
group, non–RAM-CL group, and non-CL group.
Comparing age at death among the 3 defined groups
revealed overall differences between the RAM-CL,
non–RAM-CL, and non-CL groups (ANOVA, p 
0.004). Post hoc testing showed that a lower mean
age at death was found in the RAM-CL group than
in the non–RAM-CL group or the non-CL group
(mean age of the RAM-CL group was 53.5 years,
mean age of the non–RAM-CL group was 68.7
years, and mean age of the non-CL group was 66.9
years; RAM-CL group vs non–RAM-CL group: p 
0.05 and RAM-CL group vs non-CL group: p 
0.01) (figure 3). Interestingly, no difference in age at
death was found between the non–RAM-CL group
and the non-CL group (figure 3A). Furthermore, dif-
ferences in disease duration were also found among
the 3 groups (ANOVA, p 0.024). Post hoc, signif-
icantly shorter disease duration was found for the
RAM-CL group (mean 20.9 years) than for the
non-CL group (mean 34.5 years, p  0.05) (figure
3B). After correction for multiple comparisons, no
significant difference was found in disease duration
between the RAM-CL group and the non–RAM-CL
group (mean 32.8 years) (figure 3B). Finally, the age
at disease onset did not differ among the 3 groups
(mean RAM-CL group 31.5 years, mean non–
RAM-CL group 35.9 years, and mean non-CL group
34.6 years; Kruskal-Wallis test, p  0.50; data not
shown).
Patients with PP MS were distinctly overrepre-
sented in the non-CL group (16 of 19 patients). One
patient had an SP disease subtype and one patient
had a PR disease subtype. For one patient the disease
subtype could not be retrospectively determined. In
the RAM-CL and non–RAM-CL groups, no specific
MS disease subtype was found to be clearly dominant.
Table 2 Cortical demyelination andWMLs in MS
Group and
patient
Cortical
demyelination,%
Cortical
demyelination
with RAM,%
No. of WMLs
Active
WMLs
Chronic active
WMLs
Inactive
WMLs
NonRAM-CL
1 9.9 0 0 0 3
2 24.6 0 0 2 14
3 18.3 0 0 3 29
4 11.0 0 0 0 4
5 10.5 0 0 0 15
6 20.9 0 0 3 15
7 17.6 0 0 0 2
8 20.5 0 0 0 11
9 13.4 0 0 0 6
10 24.0 0 0 7 1
RAM-CL
1 42.0 20 4 6 11
2 8.9 13 7 1 15
3 26.0 39 17 11 0
4 34.7 71 20 24 1
5 28.8 19 0 31 1
6 13.7 18 1 23 16
7 32.6 62 3 28 4
8 29.7 15 3 44 3
9 57.8 54 0 17 4
10 17.0 53 4 45 19
11 22.2 7 0 0 6
12 21.8 76 0 7 28
Non-CL
1 0.5 0 0 2 8
2 2.3 0 0 0 21
3 0 0 0 0 0
4 1.1 0 2 16 13
5 0 0 0 0 22
6 1.4 0 0 0 6
7 0.8 0 1 2 4
8 0 0 0 0 0
9 0 0 0 0 0
10 0 0 0 2 0
11 1.1 0 1 0 10
12 0.5 0 0 0 5
13 1.0 0 0 0 17
14 0 0 0 0 2
15 1.0 0 1 33 9
16 0 0 0 6 2
17 0 0 1 0 1
18 0 0 3 3 0
19 0 0 0 0 3
Abbreviations: CL cortical lesion; MSmultiple sclerosis; RAM rim of activated micro-
glia; WMLwhite matter lesion.
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Correlations of pathologic and clinical characteristics.
Several pathologic and clinical parameters were ana-
lyzed for possible associations. As expected based on
the data presented above, the presence of RAM-CLs
was associated with a younger age at death in the CL
group (Spearman   0.70, p  0.0003). The ex-
tent of RAM-CLs was also associated with a shorter
disease duration in the CL group (Spearman  
0.60, p 0.004). The age of disease onset was not
associated with the extent of microglia activation at
CL borders (Pearson r  0.13, p  0.57).
The number of chronic active WMLs also corre-
lated significantly with a younger age at death (Spear-
man   0.79, p  0.0001) and shorter disease
duration (Spearman   0.70, p  0.0005) in the
CL group. However, the number of chronic active
WMLs was not associated with either age at death or
disease duration in the non-CL group (Spearman
  0.20, p  0.20 and Spearman   0.12, p 
0.62, respectively). In the CL group, the number of
active WMLs was also associated with a younger age
at death and a shorter disease duration, although this
association was much weaker (Spearman 0.42,
p  0.05 and Spearman   0.56, p  0.008,
respectively). No association between age at death or
disease duration and the number of inactive WMLs
was found (Spearman   0.01, p  0.96 and
Spearman 0.08, p 0.73, respectively). In the
non-CL group, the presence of inactive WMLs cor-
related with a younger age at death (Spearman  
0.53, p  0.02), whereas disease duration was not
associated with the number of inactive WMLs
(Spearman   0.25, p  0.32).
Interestingly, the presence of chronic active
WMLs was associated with a higher load of RAM-
CLs in the RAM-CL group (Spearman   0.74,
p 0.0001). Furthermore, leukocortical lesions were
most prominently present in the RAM-CL group
(128 leukocortical lesions) and to a lesser extent in
the non–RAM-CL group (15 leukocortical lesions)
and non-CL group (17 leukocortical lesions). Overall
(i.e., in the CL group), no correlation was found be-
tween the number of inactive WMLs and non–
RAM-CLs (Spearman   0.07; p  0.76).
DISCUSSION This study investigated brain mate-
rial from 41 well-characterized MS autopsy cases and
showed that there is no difference regarding age at
death or disease duration between patients with
many CLs (termed the CL group) and patients with
few CLs (termed the non-CL group). In a subset of
patients within the CL group (i.e., 12 patients), a
significant proportion of the CLs were characterized
by a rim of activated microglia at their border (the
RAM-CL group).11,14 The CLs of the remaining 10
patients included in the CL group were completely
devoid of any sign of microglia activation at their
borders (the non–RAM-CL group). There was sig-
nificantly more demyelination of the cerebral cortex
in the RAM-CL group than in the non–RAM-CL
group. Regarding age at death and age at disease on-
set, no differences were observed between the
non-CL group and the non–RAM-CL group. How-
ever, a significant younger age at death was found in
patients with MS with RAM-CLs compared with pa-
tients with MS in the non–RAM-CL group or in the
Figure 3 Younger age at death and a shorter disease duration in patients with MS harboring cortical lesions
with rims of activatedmicroglia (RAM)
(A) Patients with MS harboring RAM cortical lesions (RAM-CLs) had a younger mean age at death (mean 53.5 years) than
patients with only non-RAM-CLs (mean 68.7 years) or the group without CLs (non-CL) (mean 66.9 years) (RAM-CL group vs
non-RAM-CL group p  0.05 and RAM-CL group vs non-CL group p  0.01). (B) Patients with MS harboring RAM CLs also
experienced a shorter disease duration (mean 20.9 years) than the non-CL group (mean 34.5 years) and non-RAM-CL group
(mean 32.8 years) (RAM-CL group vs non-CL group p0.05 and RAM-CL group vs non–RAM-CL group not significant). *p
0.05;**p 0.01.
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non-CL group. In addition, a shorter disease dura-
tion was found in patients with MS in the RAM-CL
group compared with patients with MS in the
non-CL group or in the non–RAM-CL group (al-
though the latter comparison did not reach statistical
significance, most likely due to the small sample size
[n  10]). Remarkably, patients with PP MS were
distinctly overrepresented in the non-CL group. Al-
though tissue selection was performed blinded to the
patients’ clinical statuses, it remains to be determined
whether this finding is of clinical significance and
could, for example, be explained by the fact that pa-
tients with PP MS tend to have a less inflammatory
profile.19 In line with our results (7 of 22 patients in
the CL group experienced a PP disease course), pre-
vious studies have clearly indicated that extensive
cortical demyelination can also occur in patients with
PP MS.9,10,14 In the general MS population, 10%–
15% of patients with MS experience a PP disease
course.19 Accordingly, the same percentage of pa-
tients with PP MS should be found in our postmor-
tem sample. However, the percentage of patients
with PP MS in our tissue bank was higher than the
expected 10%–15%, which might partly explain the
overrepresentation of patients with PP MS in our
non-CL group.
Analysis of several histopathologic characteristics
among the 3 different groups indicated that the pres-
ence of RAM-CLs was significantly associated with a
younger age at death as well as a shorter disease dura-
tion. For the CL group, the presence of chronic ac-
tive WMLs was also associated with a younger age at
death and shorter disease duration. Furthermore, we
found that the presence of chronic active WMLs was
associated with a higher RAM-CL load. Previous
studies have suggested a significant role for (slowly
expanding) chronic active WMLs in MS disease
progression.20 Based on our neuropathologic data,
we here suggest that CLs with RAM may similarly
contribute to MS disease progression and disease
severity.
The underlying etiopathogenic mechanisms of
cortical demyelination are not clear, although several
studies have suggested that cortical demyelination
may be the result of inflammation in the leptomenin-
ges.10–12 In our previous work, we were not able to
confirm this association.13 Recent work by Lucchi-
netti et al.17 based on biopsy material from patients
with early MS with tumefactive lesions showed that
CLs not only occur early in the disease course but
also are the result of an active inflammatory demyeli-
nating process.17 The researcher described the pres-
ence of myelin-laden macrophages and T-cell influx
in CLs, something that is extremely rare in CLs at the
end stage of disease.11,14 In contrast, microglia activa-
tion at the border of subpial CLs is far more regularly
found at autopsy.11,14 Although the exact pathophys-
iologic role that activated microglia might play in
these CLs is unclear, the strong positive correlation
with chronic active WMLs found in this study may
suggest an overall more pronounced activity of the
innate immunity in disease progression in a subset of
patients with MS. Previously, Magliozzi et al.21,22
showed in a subset of patients with SP MS that mi-
croglia activation and a more severely damaged cere-
bral cortex is associated with a less favorable disease
course and that these microglia may express harmful
molecules such as inducible nitric oxide and tumor
necrosis factor. Future researchers should detail
whether the presence of (activated) microglia in MS
CLs is mainly harmful23,24,25 or whether these cells
may also have neuroprotective effects in the MS cere-
bral cortex.14,21,22,26,27
In addition, as shown previously in animal mod-
els of MS (namely, experimental autoimmune
encephalomyelitis),28 the initiation of cortical demy-
elination was shown to be influenced by certain ma-
jor histocompatibility complex haplotypes. As such,
it would be of major interest to see whether genetic
markers that have ensued from recent MS suscepti-
bility studies29–32 are associated with the differences
in neuropathologic features as seen in the different
MS subgroups described here. More specifically, it
would be important to explore whether there are
haplotype differences between patients with and
without extensive cortical demyelination and be-
tween patients exhibiting RAM-CLs vs patients with
non–RAM-CLs.
Our study provides new insight into the clinico-
pathologic associations of CLs with RAM and MS
disease course, as well as into the relationship be-
tween gray and white matter pathologic lesions.
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